Insights into melanoma: targeting the mTOR pathway for therapeutics

Bibliography

• Tolleson WH. Human melanocyte biology, toxicology, and pathology. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2005;23(2):105-61
   Google Scholar
• Didolkar MS, Elias EG, Barber NA, Biologic behavior of ocular malignant melanoma and comparison with melanoma of the head and neck. Am J Surg 1980;140(4):522-6
   Google Scholar
• Available from: www.cancer.org
   Google Scholar
• Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004;150(2):179-85
   PubMed Web of Science ®Google Scholar
• Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83(8):1664-78
   PubMed Web of Science ®Google Scholar
• Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365(9460):687-701
   PubMed Web of Science ®Google Scholar
• Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005;115(4):813-24
   PubMed Web of Science ®Google Scholar
• Bliss JM, Ford D, Swerdlow AJ, Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer 1995;62(4):367-76
   Google Scholar
• Grulich AE, Bataille V, Swerdlow AJ, Naevi and pigmentary characteristics as risk factors for melanoma in a high-risk population: a case-control study in New South Wales, Australia. Int J Cancer 1996;67(4):485-91
   Google Scholar
• Tucker MA, Halpern A, Holly EA, Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997;277(18):1439-44
   PubMedGoogle Scholar
• Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 1992;8(6):400-14
   Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27(36):6199-206
   PubMed Web of Science ®Google Scholar
• Curtin JA, Fridlyand J, Kageshita T, Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353(20):2135-47
   PubMed Web of Science ®Google Scholar
• Lara MF, Paramio JM. The Rb family connects with the Tp53 family in skin carcinogenesis. Mol Carcinog 2007;46(8):618-23
   Google Scholar
• Goldstein AM, Chan M, Harland M, High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006;66(20):9818-28
   PubMed Web of Science ®Google Scholar
• Kefford RF, Newton Bishop JA, Bergman W, Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999;17(10):3245-51
   PubMed Web of Science ®Google Scholar
• Tsao H, Zhang X, Kwitkiwski K, Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol 2000;136(9):1118-22
   PubMedGoogle Scholar
• Begg CB, Orlow I, Hummer AJ, Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 2005;97(20):1507-15
   PubMedGoogle Scholar
• Dobrowolski R, Hein R, Buettner R, Loss of p14ARF expression in melanoma. Arch Dermatol Res 2002;293(11):545-51
   Google Scholar
• Sanki A, Li W, Colman M, Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma. Pathology 2007;39(6):551-7
   PubMed Web of Science ®Google Scholar
• Goldstein AM, Chidambaram A, Halpern A, Rarity of CDK4 germline mutations in familial melanoma. Melanoma Res 2002;12(1):51-5
   Google Scholar
• Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005;30(11):630-41
   PubMed Web of Science ®Google Scholar
• Cone RD, Lu D, Koppula S, The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Recent Prog Horm Res 1996;51:287-317; discussion 318
   PubMedGoogle Scholar
• Hayward NK. Genetics of melanoma predisposition. Oncogene 2003;22(20):3053-62
   Google Scholar
• Box NF, Duffy DL, Chen W, MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001;69(4):765-73
   PubMed Web of Science ®Google Scholar
• Fargnoli MC, Altobelli E, Keller G, Contribution of melanocortin-1 receptor gene variants to sporadic cutaneous melanoma risk in a population in central Italy: a case-control study. Melanoma Res 2006;16(2):175-82
   Google Scholar
• Debniak T, Scott RJ, Huzarski T, CDKN2A common variant and multi-organ cancer risk–a population-based study. Int J Cancer 2006;118(12):3180-2
   Google Scholar
• Schaffer JV, Bolognia JL. The melanocortin-1 receptor: red hair and beyond. Arch Dermatol 2001;137(11):1477-85
   Google Scholar
• Gwosdz C, Scheckenbach K, Lieven O, Comprehensive analysis of the p53 status in mucosal and cutaneous melanomas. Int J Cancer 2006;118(3):577-82
   Google Scholar
• Healy E, Reynolds NJ, Smith MD, Dissociation of erythema and p53 protein expression in human skin following UVB irradiation, and induction of p53 protein and mRNA following application of skin irritants. J Invest Dermatol 1994;103(4):493-9
   Google Scholar
• Ha L, Ichikawa T, Anver M, ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci USA 2007;104(26):10968-73
   Google Scholar
• Dahl C, Guldberg P. The genome and epigenome of malignant melanoma. APMIS 2007;115(10):1161-76
   PubMed Web of Science ®Google Scholar
• Smalley KS, Contractor R, Haass NK, An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res 2007;67(1):209-17
   Google Scholar
• Cohen SJ, Leichman CG, Yeslow G, Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin Cancer Res 2002;8(7):2116-22
   Google Scholar
• Dhawan P, Singh AB, Ellis DL, Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 2002;62(24):7335-42
   Google Scholar
• Stahl JM, Sharma A, Cheung M, Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004;64(19):7002-10
   PubMed Web of Science ®Google Scholar
• Ichii-Nakato N, Takata M, Takayanagi S, High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. J Invest Dermatol 2006;126(9):2111-18
   Google Scholar
• van Dijk MC, Bernsen MR, Ruiter DJ. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma. Am J Surg Pathol 2005;29(9):1145-51
   Google Scholar
• Omholt K, Platz A, Kanter L, NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003;9(17):6483-8
   PubMed Web of Science ®Google Scholar
• Wellbrock C, Ogilvie L, Hedley D, V599EB-RAF is an oncogene in melanocytes. Cancer Res 2004;64(7):2338-42
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54
   PubMed Web of Science ®Google Scholar
• Liu W, Kelly JW, Trivett M, Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol 2007;127(4):900-5
   Google Scholar
• Reifenberger J, Knobbe CB, Sterzinger AA, Frequent alterations of ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 2004;109(3):377-84
   Google Scholar
• Lang J, MacKie RM. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J Invest Dermatol 2005;125(3):575-9
   Google Scholar
• Saldanha G, Potter L, Daforno P, Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res 2006;12(15):4499-505
   Google Scholar
• Sasaki Y, Niu C, Makino R, BRAF point mutations in primary melanoma show different prevalences by subtype. J Invest Dermatol 2004;123(1):177-83
   Google Scholar
• Lang J, Boxer M, MacKie R. Absence of exon 15 BRAF germline mutations in familial melanoma. Hum Mutat 2003;21(3):327-30
   Google Scholar
• Saldanha G, Purnell D, Fletcher A, High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer 2004;111(5):705-10
   Google Scholar
• Michaloglou C, Vredeveld LC, Soengas MS, BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005;436(7051):720-4
   PubMed Web of Science ®Google Scholar
• Michaloglou C, Vredeveld LC, Mooi WJ, BRAF(E600) in benign and malignant human tumours. Oncogene 2008;27(7):877-95
   PubMed Web of Science ®Google Scholar
• Gorden A, Osman I, Gai W, Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003;63(14):3955-7
   PubMed Web of Science ®Google Scholar
• Ball NJ, Yohn JJ, Morelli JG, Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994;102(3):285-90
   PubMed Web of Science ®Google Scholar
• Jiveskog S, Ragnarsson-Olding B, Platz A, N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J Invest Dermatol 1998;111(5):757-61
   PubMed Web of Science ®Google Scholar
• van Elsas A, Zerp SF, van der Flier S, Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 1996;149(3):883-93
   PubMed Web of Science ®Google Scholar
• Eskandarpour M, Hashemi J, Kanter L, Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. J Natl Cancer Inst 2003;95(11):790-8
   Google Scholar
• Bauer J, Curtin JA, Pinkel D, Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol 2007;127(1):179-82
   PubMed Web of Science ®Google Scholar
• Indsto JO, Kumar S, Wang L, Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions. J Cutan Pathol 2007;34(6):448-55
   Google Scholar
• Omholt K, Karsberg S, Platz A, Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res 2002;8(11):3468-74
   PubMed Web of Science ®Google Scholar
• Dai DL, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 2005;23(7):1473-82
   PubMedGoogle Scholar
• Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene 2003;22(20):3113-22
   PubMed Web of Science ®Google Scholar
• Reifenberger J, Wolter M, Bostrom J, Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Arch 2000;436(5):487-93
   Google Scholar
• Tsao H, Zhang X, Benoit E, Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998;16(26):3397-402
   PubMed Web of Science ®Google Scholar
• Tsao H, Zhang X, Fowlkes K, Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000;60(7):1800-4
   PubMed Web of Science ®Google Scholar
• Tsao H, Goel V, Wu H, Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004;122(2):337-41
   PubMed Web of Science ®Google Scholar
• Davies MA, Stemke-Hale K, Tellez C, A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 2008;99(8):1265-8
   PubMed Web of Science ®Google Scholar
• Meier F, Schittek B, Busch S, The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 2005;10:2986-3001
   PubMed Web of Science ®Google Scholar
• Cheung M, Sharma A, Madhunapantula SV, Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 2008;68(9):3429-39
   Google Scholar
• Populo H, Soares P, Faustino A, mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. Pigment Cell Melanoma Res 2011;24(1):254-7
   Google Scholar
• Smalley KS, Eisen TG. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer 2003;105(2):165-75
   PubMed Web of Science ®Google Scholar
• Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006;25(48):6436-46
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12(1):9-22
   PubMed Web of Science ®Google Scholar
• Wiltshire RN, Duray P, Bittner ML, Direct visualization of the clonal progression of primary cutaneous melanoma: application of tissue microdissection and comparative genomic hybridization. Cancer Res 1995;55(18):3954-7
   Google Scholar
• Cruz J, Reis-Filho JS, Silva P, Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology 2003;65(1):72-82
   PubMed Web of Science ®Google Scholar
• Rosen EM, Nigam SK, Goldberg ID. Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction. J Cell Biol 1994;127(6 Pt 2):1783-7
   Google Scholar
• Li G, Schaider H, Satyamoorthy K, Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 2001;20(56):8125-35
   Google Scholar
• Danen EH, Ten Berge PJ, Van Muijen GN, Emergence of alpha 5 beta 1 fibronectin- and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology 1994;24(3):249-56
   PubMed Web of Science ®Google Scholar
• Danen EH, de Vries TJ, Morandini R, E-cadherin expression in human melanoma. Melanoma Res 1996;6(2):127-31
   Google Scholar
• Lassam N, Bickford S. Loss of c-kit expression in cultured melanoma cells. Oncogene 1992;7(1):51-6
   Google Scholar
• Ohashi A, Funasaka Y, Ueda M, c-KIT receptor expression in cutaneous malignant melanoma and benign melanotic naevi. Melanoma Res 1996;6(1):25-30
   Google Scholar
• Willmore-Payne C, Holden JA, Tripp S, Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 2005;36(5):486-93
   PubMed Web of Science ®Google Scholar
• Curtin JA, Busam K, Pinkel D, Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24(26):4340-6
   PubMed Web of Science ®Google Scholar
• Huang S, Jean D, Luca M, Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J 1998;17(15):4358-69
   Google Scholar
• Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281(5381):1322-6
   PubMed Web of Science ®Google Scholar
• Raisova M, Bektas M, Wieder T, Resistance to CD95/Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release. FEBS Lett 2000;473(1):27-32
   Google Scholar
• Thomas WD, Zhang XD, Franco AV, TNF-related apoptosis-inducing ligand-induced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of mitochondria. J Immunol 2000;165(10):5612-20
   PubMed Web of Science ®Google Scholar
• Hossini AM, Eberle J, Fecker LF, Conditional expression of exogenous Bcl-X(S) triggers apoptosis in human melanoma cells in vitro and delays growth of melanoma xenografts. FEBS Lett 2003;553(3):250-6
   Google Scholar
• Selzer E, Schlagbauer-Wadl H, Okamoto I, Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res 1998;8(3):197-203
   PubMed Web of Science ®Google Scholar
• Fecker LF, Geilen CC, Tchernev G, Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol 2006;126(6):1366-71
   Web of Science ®Google Scholar
• Zhuang L, Lee CS, Scolyer RA, Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol 2007;20(4):416-26
   PubMed Web of Science ®Google Scholar
• Karst AM, Dai DL, Martinka M, PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene 2005;24(6):1111-16
   PubMed Web of Science ®Google Scholar
• Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007;12(9):1543-68
   Google Scholar
• Kluger HM, McCarthy MM, Alvero AB, The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by phenoxodiol is associated with Carboplatin sensitization. J Transl Med 2007;5:6
   PubMed Web of Science ®Google Scholar
• Chawla-Sarkar M, Bae SI, Reu FJ, Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2004;11(8):915-23
   PubMed Web of Science ®Google Scholar
• Schmollinger JC, Vonderheide RH, Hoar KM, Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci USA 2003;100(6):3398-403
   Google Scholar
• Goding CR. Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev 2000;14(14):1712-28
   Google Scholar
• Gaggioli C, Busca R, Abbe P, Microphthalmia-associated transcription factor (MITF) is required but is not sufficient to induce the expression of melanogenic genes. Pigment Cell Res 2003;16(4):374-82
   Google Scholar
• Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 2006;12(9):406-14
   PubMed Web of Science ®Google Scholar
• Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res 2007;67(6):2632-42
   Google Scholar
• Garraway LA, Widlund HR, Rubin MA, Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005;436(7047):117-22
   PubMed Web of Science ®Google Scholar
• Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445(7130):851-7
   PubMed Web of Science ®Google Scholar
• Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22(20):3138-51
   PubMed Web of Science ®Google Scholar
• Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007;109(3):455-64
   PubMed Web of Science ®Google Scholar
• Middleton MR, Grob JJ, Aaronson N, Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18(1):158-66
   PubMed Web of Science ®Google Scholar
• Atallah E, Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 2005;6(3):185-93
   Google Scholar
• Tarhini AA, Agarwala SS. Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 2006;19(1):19-25
   PubMed Web of Science ®Google Scholar
• Bukowski RM. Pegylated interferon alfa-2b as treatment of patients with solid tumors. Curr Oncol Rep 2003;5(2):87-8
   Google Scholar
• Eggermont AM, Suciu S, Santinami M, Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372(9633):117-26
   PubMed Web of Science ®Google Scholar
• Culver ME, Gatesman ML, Mancl EE, Ipilimumab: a novel treatment for metastatic melanoma. Ann Pharmacother 2011;45(4):510-19
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363(9):809-19
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507-16
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
   PubMed Web of Science ®Google Scholar
• Hauschild A, Agarwala SS, Trefzer U, Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27(17):2823-30
   PubMed Web of Science ®Google Scholar
• Solit DB, Garraway LA, Pratilas CA, BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439(7074):358-62
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Krishnamurthi SS, Rinehart JJ, Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010;16(6):1924-37
   PubMed Web of Science ®Google Scholar
• Adjei AA, Cohen RB, Franklin W, Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26(13):2139-46
   PubMed Web of Science ®Google Scholar
• Schad K, Baumann Conzett K, Zipser MC, Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 2010;16(3):1058-64
   PubMed Web of Science ®Google Scholar
• Infante JR, Fecher LA, Nallapareddy S, Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. J Clin Oncol 2010;28(Suppl 15s):abstract 2503
   Google Scholar
• Kim KB, Eton O, Davis DW, Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008;99(5):734-40
   PubMed Web of Science ®Google Scholar
• Woodman SE, Trent JC, Stemke-Hale K, Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 2009;8(8):2079-85
   PubMed Web of Science ®Google Scholar
• von Moos R, Seifert B, Simcock M, First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol 2012;23(2):531-6
   PubMed Web of Science ®Google Scholar
• Cook N, Basu B, Biswas S, A phase 2 study of vatalanib in metastatic melanoma patients. Eur J Cancer 2010;46(15):2671-3
   Google Scholar
• Fruehauf JP, Lutzky J, McDermott DF, Axitinib (AG-013736) in patients with metastatic melanoma: a phase II study. J Clin Oncol 2008;26(15 Suppl):9006
   Google Scholar
• Kim KB, Saro J, Moschos SS, A phase I dose finding and biomarker study of TKI258 (dovitinib lactate) in patients with advanced melanoma. J Clin Oncol 2008;26(15 Suppl):9026
   Google Scholar
• Molhoek KR, Brautigan DL, Slingluff CL Jr. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med 2005;3:39
   PubMed Web of Science ®Google Scholar
• Romano MF, Avellino R, Petrella A, Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur J Cancer 2004;40(18):2829-36
   PubMed Web of Science ®Google Scholar
• Eberle J, Kurbanov BM, Hossini AM, Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Drug Resist Updat 2007;10(6):218-34
   Google Scholar
• O'Reilly KE, Rojo F, She QB, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66(3):1500-8
   PubMed Web of Science ®Google Scholar
• Werzowa J, Koehrer S, Strommer S, Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. J Invest Dermatol 2011;131(2):495-503
   PubMed Web of Science ®Google Scholar
• Aziz SA, Jilaveanu LB, Zito C, Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res 2010;16(24):6029-39
   PubMed Web of Science ®Google Scholar
• Werzowa J, Cejka D, Fuereder T, Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002. Br J Dermatol 2009;160(5):955-64
   Google Scholar
• Deng W, Vashisht Gopal YN, Scott A, Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res 2011;25(2):248-58
   Google Scholar
• Atefi M, von Euw E, Attar N, Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 2011;6(12):e28973
   PubMed Web of Science ®Google Scholar
• Su F, Bradley WD, Wang Q, Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res 2012;72(4):969-78
   PubMed Web of Science ®Google Scholar
• Thallinger C, Poeppl W, Pratscher B, CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model. Pharmacology 2007;79(4):207-13
   Google Scholar
• Bergman L, Seregard S, Nilsson B, Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci 2002;43(8):2579-83
   Google Scholar
• Edge S, Byrd D, Compton C, American joint committee on cancer staging manual. 7th edition. Springer; New York: 2010
   Google Scholar
• Singh AD, De Potter P, Fijal BA, Lifetime prevalence of uveal melanoma in white patients with oculo(dermal) melanocytosis. Ophthalmology 1998;105(1):195-8
   PubMed Web of Science ®Google Scholar
• Sumich P, Mitchell P, Wang JJ. Choroidal nevi in a white population: the Blue Mountains Eye Study. Arch Ophthalmol 1998;116(5):645-50
   Google Scholar
• McLean IW, Foster WD, Zimmerman LE, Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol 1983;96(4):502-9
   PubMedGoogle Scholar
• Isager P, Engholm G, Overgaard J, Uveal and conjunctival malignant melanoma in denmark 1943-97: observed and relative survival of patients followed through 2002. Ophthalmic Epidemiol 2006;13(2):85-96
   PubMed Web of Science ®Google Scholar
• Diener-West M, Hawkins BS, Markowitz JA, A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 1992;110(2):245-50
   PubMedGoogle Scholar
• Coleman K, Baak JP, Van Diest P, Prognostic factors following enucleation of 111 uveal melanomas. Br J Ophthalmol 1993;77(11):688-92
   PubMed Web of Science ®Google Scholar
• Mooy CM, De Jong PT. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 1996;41(3):215-28
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Egan KM, Seddon JM, Survival of patients with metastases from uveal melanoma. Ophthalmology 1991;98(3):383-9; discussion 390
   PubMed Web of Science ®Google Scholar
• McLean IW. The biology of haematogenous metastasis in human uveal malignant melanoma. Virchows Arch A Pathol Anat Histopathol 1993;422(6):433-7
   PubMedGoogle Scholar
• Seregard S. Conjunctival melanoma. Surv Ophthalmol 1998;42(4):321-50
   PubMed Web of Science ®Google Scholar
• Folberg R, McLean IW, Zimmerman LE. Primary acquired melanosis of the conjunctiva. Hum Pathol 1985;16(2):129-35
   Google Scholar
• Tuomaala S, Kivela T. Metastatic pattern and survival in disseminated conjunctival melanoma: implications for sentinel lymph node biopsy. Ophthalmology 2004;111(4):816-21
   Google Scholar
• Esmaeli B, Wang X, Youssef A, Patterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades. Ophthalmology 2001;108(11):2101-5
   PubMed Web of Science ®Google Scholar
• Anastassiou G, Heiligenhaus A, Bechrakis N, Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study. Br J Ophthalmol 2002;86(2):163-7
   PubMed Web of Science ®Google Scholar
• Paridaens AD, Minassian DC, McCartney AC, Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases. Br J Ophthalmol 1994;78(4):252-9
   PubMed Web of Science ®Google Scholar
• Jakobiec FA, Rini FJ, Fraunfelder FT, Cryotherapy for conjunctival primary acquired melanosis and malignant melanoma. Experience with 62 cases. Ophthalmology 1988;95(8):1058-70
   Google Scholar
• Speicher MR, Prescher G, du Manoir S, Chromosomal gains and losses in uveal melanomas detected by comparative genomic hybridization. Cancer Res 1994;54(14):3817-23
   PubMedGoogle Scholar
• Parrella P, Caballero OL, Sidransky D, Detection of c-myc amplification in uveal melanoma by fluorescent in situ hybridization. Invest Ophthalmol Vis Sci 2001;42(8):1679-84
   PubMed Web of Science ®Google Scholar
• Hendrix MJ, Seftor EA, Seftor RE, Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF). Am J Pathol 1998;152(4):855-63
   Web of Science ®Google Scholar
• Zuidervaart W, van Nieuwpoort F, Stark M, Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 2005;92(11):2032-8
   PubMed Web of Science ®Google Scholar
• Populo H, Soares P, Rocha AS, Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res 2010;20(2):107-17
   PubMed Web of Science ®Google Scholar
• Populo H, Vinagre J, Lopes JM, Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas. Br J Ophthalmol 2011;95(5):715-19
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk CD, Bezrookove V, Green G, Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457(7229):599-602
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk CD, Fitch KR, Fuchs H, Effects of G-protein mutations on skin color. Nat Genet 2004;36(9):961-8
   Google Scholar
• Van Raamsdonk CD, Griewank KG, Crosby MB, Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363(23):2191-9
   PubMed Web of Science ®Google Scholar
• Saraiva VS, Caissie AL, Segal L, Immunohistochemical expression of phospho-Akt in uveal melanoma. Melanoma Res 2005;15(4):245-50
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman MH, Yang Y, Zhou XP, High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J Clin Oncol 2006;24(2):288-95
   PubMed Web of Science ®Google Scholar
• Mouriaux F, Kherrouche Z, Maurage CA, Expression of the c-kit receptor in choroidal melanomas. Melanoma Res 2003;13(2):161-6
   Google Scholar
• Prescher G, Bornfeld N, Hirche H, Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996;347(9010):1222-5
   PubMed Web of Science ®Google Scholar
• Woodward JK, Rennie IG, Burn JL, A potential role for TGFbeta in the regulation of uveal melanoma adhesive interactions with the hepatic endothelium. Invest Ophthalmol Vis Sci 2005;46(10):3473-7
   Google Scholar
• Parrella P, Sidransky D, Merbs SL. Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway. Cancer Res 1999;59(13):3032-7
   PubMedGoogle Scholar
• Sisley K, Rennie IG, Parsons MA, Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 1997;19(1):22-8
   PubMed Web of Science ®Google Scholar
• Aalto Y, Eriksson L, Seregard S, Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci 2001;42(2):313-17
   PubMed Web of Science ®Google Scholar
• Hoglund M, Gisselsson D, Hansen GB, Dissecting karyotypic patterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution. Int J Cancer 2004;108(1):57-65
   PubMedGoogle Scholar
• White VA, McNeil BK, Horsman DE. Acquired homozygosity (isodisomy) of chromosome 3 in uveal melanoma. Cancer Genet Cytogenet 1998;102(1):40-5
   Google Scholar
• Brantley MA Jr, Harbour JW. Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol 2000;157(6):1795-801
   PubMedGoogle Scholar
• Coupland SE, Anastassiou G, Stang A, The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. J Pathol 2000;191(2):120-6
   Google Scholar
• van der Velden PA, Metzelaar-Blok JA, Bergman W, Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res 2001;61(13):5303-6
   PubMed Web of Science ®Google Scholar
• Paraoan L, Gray D, Hiscott P, Expression of p53-induced apoptosis effector PERP in primary uveal melanomas: downregulation is associated with aggressive type. Exp Eye Res 2006;83(4):911-19
   Google Scholar
• McNamara M, Felix C, Davison EV, Assessment of chromosome 3 copy number in ocular melanoma using fluorescence in situ hybridization. Cancer Genet Cytogenet 1997;98(1):4-8
   PubMedGoogle Scholar
• Spendlove HE, Damato BE, Humphreys J, BRAF mutations are detectable in conjunctival but not uveal melanomas. Melanoma Res 2004;14(6):449-52
   PubMed Web of Science ®Google Scholar
• Goldenberg-Cohen N, Cohen Y, Rosenbaum E, T1799A BRAF mutations in conjunctival melanocytic lesions. Invest Ophthalmol Vis Sci 2005;46(9):3027-30
   Google Scholar
• Populo H, Soares P, Rocha AS, Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res 2011;20(2):107-17
   Google Scholar
• Damato B. Developments in the management of uveal melanoma. Clin Experiment Ophthalmol 2004;32(6):639-47
   PubMed Web of Science ®Google Scholar
• Ambrosini G, Schwartz GK. The MEK inhibitor AZD6244 is active in GNAQ mutant ocular melanoma cells. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research. 17-21;Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl): Abstract nr 5035.
   Google Scholar
• Mitsiades N, Chew SA, He B, Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest Ophthalmol Vis Sci 2011;52(10):7248-55
   PubMed Web of Science ®Google Scholar
• Amiri KI, Horton LW, LaFleur BJ, Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 2004;64(14):4912-18
   Google Scholar
• Facchetti F, Previdi S, Ballarini M, Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 2004;9(5):573-82
   Google Scholar
• Knight R. IMiDs: a novel class of immunomodulators. Semin Oncol 2005;32(4 Suppl 5):S24-30
   PubMed Web of Science ®Google Scholar
• Knight LA, Di Nicolantonio F, Whitehouse PA, The effect of imatinib mesylate (Glivec) on human tumor-derived cells. Anticancer Drugs 2006;17(6):649-55
   Google Scholar
• Pietras K, Ostman A, Sjoquist M, Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61(7):2929-34
   PubMed Web of Science ®Google Scholar
• Calipel A, Mouriaux F, Glotin AL, Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells. J Biol Chem 2006;281(14):9238-50
   Google Scholar
• Collisson EA, De A, Suzuki H, Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res 2003;63(18):5669-73
   Google Scholar
• Holash J, Davis S, Papadopoulos N, VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99(17):11393-8
   PubMed Web of Science ®Google Scholar
• Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25(7):884-96
   PubMed Web of Science ®Google Scholar
• Babchia N, Calipel A, Mouriaux F, The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK. Invest Ophthalmol Vis Sci 2010;51(1):421-9
   PubMed Web of Science ®Google Scholar
• Ardjomand N, Schaffler G, Radner H, Expression of somatostatin receptors in uveal melanomas. Invest Ophthalmol Vis Sci 2003;44(3):980-7
   Google Scholar
• Available from: www.clinicaltrials.org
   Google Scholar
• Triozzi PL, Eng C, Singh AD. Targeted therapy for uveal melanoma. Cancer Treat Rev 2008;34(3):247-58
   Google Scholar